Treatment outcome, toxicity, and quality of life of patients with bronchus-associated lymphoid tissue lymphoma

References

• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi:10.1038/s41375-022-01620-2
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results Database. Cancer. 2013;119(3):629–638. doi:10.1002/cncr.27773
   PubMed Web of Science ®Google Scholar
• Wu Y, Liu X, Imber BS, et al. Influence of age on long-term net survival benefit for early-stage MALT lymphomas treated with radiotherapy: a SEER Database analysis (2000–2015). Radiother Oncol. 2022;173:179–187. doi:10.1016/j.radonc.2022.05.034
   PubMed Web of Science ®Google Scholar
• Low SK, Zayan AH, Istanbuly O, et al. Prognostic factors and nomogram for survival prediction in patients with primary pulmonary lymphoma: a SEER population-based study. Leuk Lymphoma. 2019;60(14):3406–3416. doi:10.1080/10428194.2019.1633636
   PubMed Web of Science ®Google Scholar
• Swerdlow S, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC; 2017.
   Google Scholar
• Sanguedolce F, Zanelli M, Zizzo M, et al. Primary pulmonary B-cell lymphoma: a review and update. Cancers. 2021;13(3):415. doi:10.3390/cancers13030415
   PubMed Web of Science ®Google Scholar
• Joffe E, Leyfman Y, Drill E, et al. Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue. Blood Adv. 2021;5(2):345–351. doi:10.1182/bloodadvances.2020003213
   PubMed Web of Science ®Google Scholar
• Oh SY, Kim WS, Kim JS, et al. Pulmonary marginal zone B-cell lymphoma of MALT type – what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy? Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol. 2010;89(6):563–568. doi:10.1007/s00277-009-0875-7
   PubMed Web of Science ®Google Scholar
• Sirajuddin A, Raparia K, Lewis VA, et al. Primary pulmonary lymphoid lesions: radiologic and pathologic findings. Radiographics. 2016;36(1):53–70. doi:10.1148/rg.2016140339
   PubMed Web of Science ®Google Scholar
• McCulloch GL, Sinnatamby R, Stewart S, et al. High-resolution computed tomographic appearance of MALToma of the lung. Eur Radiol. 1998;8(9):1669–1673. doi:10.1007/s003300050609
   PubMed Web of Science ®Google Scholar
• King LJ, Padley SP, Wotherspoon AC, et al. Pulmonary MALT lymphoma: imaging findings in 24 cases. Eur Radiol. 2000;10(12):1932–1938. doi:10.1007/s003300000491
   PubMed Web of Science ®Google Scholar
• Kuper-Hommel MJJ, van de Schans SAM, Vreugdenhil G, et al. Trends in incidence, therapy and outcome of localized nodal and extranodal marginal zone lymphomas: declining incidence and inferior outcome for gastrointestinal sites. Leuk Lymphoma. 2013;54(9):1891–1897. doi:10.3109/10428194.2013.764421
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Desai A. Radiation therapy administration and survival in stage I/II extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Int J Radiat Oncol Biol Phys. 2014;88(3):642–649. doi:10.1016/j.ijrobp.2013.11.225
   PubMed Web of Science ®Google Scholar
• NCCN. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: B-cell lymphomas, version 3, 2023; 2023. Available from: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
   Google Scholar
• Zucca E, Arcaini L, Buske C, et al. Marginal zone lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(1):17–29. doi:10.1016/j.annonc.2019.10.010
   PubMed Web of Science ®Google Scholar
• Teckie S, Qi S, Lovie S, et al. Long-term outcomes and patterns of relapse of early-stage extranodal marginal zone lymphoma treated with radiation therapy with curative intent. Int J Radiat Oncol Biol Phys. 2015;92(1):130–137. doi:10.1016/j.ijrobp.2015.01.040
   PubMed Web of Science ®Google Scholar
• Teckie S, Qi S, Chelius M, et al. Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma. Ann Oncol. 2017;28(5):1064–1069. doi:10.1093/annonc/mdx025
   PubMed Web of Science ®Google Scholar
• Goda JS, Gospodarowicz M, Pintilie M, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer. 2010;116(16):3815–3824. doi:10.1002/cncr.25226
   PubMed Web of Science ®Google Scholar
• Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol. 2003;21(22):4157–4164. doi:10.1200/JCO.2003.06.085
   PubMed Web of Science ®Google Scholar
• Tran KH, Campbell BA, Fua T, et al. Efficacy of low dose radiotherapy for primary orbital marginal zone lymphoma. Leuk Lymphoma. 2013;54(3):491–496. doi:10.3109/10428194.2012.717279
   PubMed Web of Science ®Google Scholar
• Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003;101(7):2489–2495. doi:10.1182/blood-2002-04-1279
   PubMed Web of Science ®Google Scholar
• Tsai HK, Li S, Ng AK, et al. Role of radiation therapy in the treatment of stage I/II mucosa-associated lymphoid tissue lymphoma. Ann Oncol. 2007;18(4):672–678. doi:10.1093/annonc/mdl468
   PubMed Web of Science ®Google Scholar
• Sammassimo S, Pruneri G, Andreola G, et al. A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG). Hematol Oncol. 2016;34(4):177–183. doi:10.1002/hon.2243
   PubMed Web of Science ®Google Scholar
• Wang L, Ye G, Liu Z, et al. Clinical characteristics, diagnosis, treatment, and prognostic factors of pulmonary mucosa-associated lymphoid tissue-derived lymphoma. Cancer Med. 2019;8(18):7660–7668. doi:10.1002/cam4.2683
   PubMed Web of Science ®Google Scholar
• Imber BS, Chau KW, Lee J, et al. Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients? Blood Adv. 2021;5(20):4185–4197. doi:10.1182/bloodadvances.2021004939
   PubMed Web of Science ®Google Scholar
• Ferraro P, Trastek VF, Adlakha H, et al. Primary non-Hodgkin’s lymphoma of the lung. Ann Thorac Surg. 2000;69(4):993–997. doi:10.1016/s0003-4975(99)01535-0
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Cascione L, Conconi A, et al. A MALT Lymphoma Prognostic Index. Blood. 2017;130(12):1409–1417. doi:10.1182/blood-2017-03-771915
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376. doi:10.1093/jnci/85.5.365
   PubMed Web of Science ®Google Scholar
• Cordier JF, Chailleux E, Lauque D, et al. Primary pulmonary lymphomas. A clinical study of 70 cases in nonimmunocompromised patients. Chest. 1993;103(1):201–208. doi:10.1378/chest.103.1.201
   PubMed Web of Science ®Google Scholar
• Kurtin PJ, Myers JL, Adlakha H, et al. Pathologic and clinical features of primary pulmonary extranodal marginal zone B-cell lymphoma of MALT type. Am J Surg Pathol. 2001;25(8):997–1008. doi:10.1097/00000478-200108000-00003
   PubMed Web of Science ®Google Scholar
• Borie R, Wislez M, Thabut G, et al. Clinical characteristics and prognostic factors of pulmonary MALT lymphoma. Eur Respir J. 2009;34(6):1408–1416. doi:10.1183/09031936.00039309
   PubMed Web of Science ®Google Scholar
• Ahmed S, Kussick SJ, Siddiqui AK, et al. Bronchial-associated lymphoid tissue lymphoma: a clinical study of a rare disease. Eur J Cancer. 2004;40(9):1320–1326. doi:10.1016/j.ejca.2004.02.006
   PubMed Web of Science ®Google Scholar
• Lee H, Yang B, Nam B, et al. Treatment outcomes in patients with extranodal marginal zone B-cell lymphoma of the lung. J Thorac Cardiovasc Surg. 2017;154(1):342–349. doi:10.1016/j.jtcvs.2017.03.043
   PubMed Web of Science ®Google Scholar
• Girinsky T, Paumier A, Ferme C, et al. Low-dose radiation treatment in pulmonary mucosa-associated lymphoid tissue lymphoma: a plausible approach? A single-institution experience in 10 patients. Int J Radiat Oncol Biol Phys. 2012;83(3):e385–e389. doi:10.1016/j.ijrobp.2012.01.005
   PubMed Web of Science ®Google Scholar
• Freret ME, Tringale KR, Boe L, et al. Very low-dose radiotherapy for extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue. Leuk Lymphoma. 2023;64(13):2195–2201. doi:10.1080/10428194.2023.2255706
   PubMed Web of Science ®Google Scholar
• Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100(1):86–92. doi:10.1016/j.radonc.2011.05.013
   PubMed Web of Science ®Google Scholar
• Hoskin P, Popova B, Schofield O, et al. 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2021;22(3):332–340. doi:10.1016/S1470-2045(20)30686-0
   PubMed Web of Science ®Google Scholar
• Zhong Q, Liu Y, Wu Y, et al. Impact of age on long-term relative survival benefit of radiotherapy for early-stage grade I–II follicular lymphoma from the SEER database (2000–2015). Leuk Lymphoma. 2024;65(3):312–322.
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Kirkwood AA, Popova B, et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. 2014;15(4):457–463. doi:10.1016/S1470-2045(14)70036-1
   PubMed Web of Science ®Google Scholar